熱門資訊> 正文
Astria TherapeuticS GAAP每股收益为-0.38美元，差0.02美元
2024-05-10 13:54
- Astria TherapeuticS press release (NASDAQ:ATXS): Q1 GAAP EPS of -$0.38 misses by $0.02.
- As of March 31, 2024, Astria had cash, cash equivalents and short-term investments of $369.9 million, compared to $246.5 million as of December 31, 2023.
- The company expects that its cash, cash equivalents and short-term investments as of March 31, 2024 will be sufficient to fund its operations into mid-2027, including all STAR-0215 program activities through the completion of a planned Q3M Phase 3 pivotal trial as well as advancing the STAR-0310 OX40 program through submission of an IND and early proof-of-concept results from a Phase 1a clinical trial.
- Net cash used in operating activities for the three months ended March 31, 2024 was $19.1 million, compared to $13.3 million for the three months ended March 31, 2023.
More on Astria TherapeuticS
- Astria TherapeuticS GAAP EPS of -$2.42 misses by $0.19
- Seeking Alpha’s Quant Rating on Astria TherapeuticS
- Historical earnings data for Astria TherapeuticS
- Financial information for Astria TherapeuticS
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
